Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic CancerResearch Question:
What is the safety, tolerability, and pharmacokinetics of SBP-101 when combined with
nab-paclitaxel and gemcitabine in patients with untreated pancreatic cancer?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This is an open-label phase 1A/1B study to assess the safety, tolerability, and movement
throughout the body (pharmacokinetics) of SBP-101 when combined with nab-paclitaxel
and gemcitabine in patients with previously untreated pancreatic cancer (metastatic
pancreatic ductal adenocarcinoma) and to identify a recommended phase 2 dose. The
study will also assess preliminary efficacy of the 3-drug treatment combination.
Study Reference #: IGIP19009
Lead Researcher (Principal Investigator)
Lead Researcher: Aram Hezel
Study Contact InformationStudy Coordinator: Chris LeFeber
Phone: (585) 275-0407
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search